Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | CTH | P32929 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41886 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL28883817 | 0.97 | HMGCR (0.39) | HMGCRCHRM1TBXA2RADRA1ACTH | |
| Hydrochloric Acid SCHEMBL1092821 | 0.97 | HMGCR (0.39) | HMGCRCHRM1TBXA2RADRA1ACTH | |
| Methane SCHEMBL27575418 | 0.97 | HMGCR (0.39) | HMGCRCHRM1TBXA2RADRA1ACTH | |
| SCHEMBL17559271 | 0.97 | HMGCR (0.39) | HMGCRCHRM1TBXA2RADRA1ACTH | |
| Acetic Acid SCHEMBL20839531 | 0.94 | CTH (0.42) | HMGCRCHRM1TBXA2RADRA1ACTH | |
| SCHEMBL28060901 | 0.89 | DPP4 (0.35) | HMGCRCHRM1TBXA2RADRA1ACTH | |
| Hydrogen Sulfide SCHEMBL27991575 | 0.87 | EGLN1 (0.37) | HMGCRCHRM1TBXA2RADRA1ACTH | |
| SCHEMBL8654274 | 0.85 | DPP4 (0.33) | HMGCRCHRM1TBXA2RADRA1ACTH | |
| SCHEMBL14805819 | 0.85 | EGLN1 (0.40) | CTHDPP4EGLN1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954269-B2 | Anti-inflammatory tripeptides | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2021-03-23 | — | — | US | disclosed |
| US-20190153029-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2019-05-23 | — | — | US | disclosed |
| US-10227379-B2 | Anti-inflammatory tripeptides | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2019-03-12 | — | — | US | disclosed |
| US-20160244484-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2016-08-25 | — | — | US | disclosed |
| EP-3049428-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | Dr. August Wolff GmbH & Co. KG Arzneimittel (DE) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015040235-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-03-26 | — | — | WO | disclosed |
| EP-1713780-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-01-18 | — | — | EP | disclosed |
| EP-2338490-A2 | Combinations Useful for the Treatment of Neuronal Disorders | Probiodrug AG (DE) | 2011-06-29 | — | — | EP | disclosed |
| US-7897633-B2 | Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism | PROBIODRUG AG (DE) | 2011-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244484-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | VIP, TNF, ENPEP | HMGCR 2160/4885CHRM1 3948/4885TBXA2R 876/4885 |
| US-20190153029-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | VIP, TNF, ENPEP | HMGCR 2160/4885CHRM1 3948/4885TBXA2R 876/4885 |
| US-10954269-B2 | Anti-inflammatory tripeptides | VIP, TNF, ENPEP | HMGCR 2160/4885CHRM1 3948/4885TBXA2R 876/4885 |
| US-10227379-B2 | Anti-inflammatory tripeptides | VIP, TNF, ENPEP | HMGCR 2160/4885CHRM1 3948/4885TBXA2R 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.